AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Research
The volume and pace of cancer research, from preclinical studies to clinical trials and FDA approvals, can make it challenging to stay informed. This section highlights the latest developments and translates complex scientific concepts into clear, accessible insights for both healthcare professionals and the broader public.
Colorectal Cancer at ASCO 2026: Stopping Immunotherapy, BRAF-Targeted Therapy, and Exercise's Role
By Stacey A. Cohen, MD
Before discussing any of the specific advances from ASCO 2026, the single most important principle in colorectal cancer is straightforward: test all patients for microsatellite instability (MSI).
Colorectal Cancer at ASCO 2026: Stopping Immunotherapy, BRAF-Targeted Therapy, and Exercise's Role
By Stacey A. Cohen, MD
Before discussing any of the specific advances from ASCO 2026, the single most important principle in colorectal cancer is straightforward: test all patients for microsatellite instability (MSI).
Colorectal Cancer at ASCO 2026: Stopping Immunotherapy, BRAF-Targeted Therapy, and Exercise's Role
By Stacey A. Cohen, MD
Before discussing any of the specific advances from ASCO 2026, the single most important principle in colorectal cancer is straightforward: test all patients for microsatellite instability (MSI).
Prostate Cancer at ASCO 2026: Perioperative Intensification, Earlier PARP Inhibitors, and De-escalation
By Alexandra Sokolova, MD
ASCO 2026 brought multiple practice-influencing trials in prostate cancer spanning localized high-risk disease, metastatic hormone-sensitive disease, and de-escalation for exceptional responders.
Prostate Cancer at ASCO 2026: Perioperative Intensification, Earlier PARP Inhibitors, and De-escalation
By Alexandra Sokolova, MD
ASCO 2026 brought multiple practice-influencing trials in prostate cancer spanning localized high-risk disease, metastatic hormone-sensitive disease, and de-escalation for exceptional responders.
Prostate Cancer at ASCO 2026: Perioperative Intensification, Earlier PARP Inhibitors, and De-escalation
By Alexandra Sokolova, MD
ASCO 2026 brought multiple practice-influencing trials in prostate cancer spanning localized high-risk disease, metastatic hormone-sensitive disease, and de-escalation for exceptional responders.
Cellular Therapies for Multiple Myeloma Part II: CAR-T Toxicities for the Community Oncologist
By Aimaz Afrough, MD; Samer Al Hadidi, MD, MS; Sean Taasan, MD; Larry D Anderson Jr, MD, PhD
While ide-cel and cilta-cel are generally considered safe and have remarkable therapeutic impact for relapsed/refractory myeloma, both agents carry a broad and clinically significant toxicity burden that practitioners must recognize and actively surveil.
Cellular Therapies for Multiple Myeloma Part II: CAR-T Toxicities for the Community Oncologist
By Aimaz Afrough, MD; Samer Al Hadidi, MD, MS; Sean Taasan, MD; Larry D Anderson Jr, MD, PhD
While ide-cel and cilta-cel are generally considered safe and have remarkable therapeutic impact for relapsed/refractory myeloma, both agents carry a broad and clinically significant toxicity burden that practitioners must recognize and actively surveil.
Cellular Therapies for Multiple Myeloma Part II: CAR-T Toxicities for the Community Oncologist
By Aimaz Afrough, MD; Samer Al Hadidi, MD, MS; Sean Taasan, MD; Larry D Anderson Jr, MD, PhD
While ide-cel and cilta-cel are generally considered safe and have remarkable therapeutic impact for relapsed/refractory myeloma, both agents carry a broad and clinically significant toxicity burden that practitioners must recognize and actively surveil.
Cellular Therapies for Multiple Myeloma Part I: A CAR-T Primer for the Community Oncologist
By Aimaz Afrough, MD; Samer Al Hadidi, MD, MS; Sean Taasan, MD; Larry D Anderson Jr, MD, PhD
Ide-cel was the first anti-BCMA CAR-T product approved by the FDA in March 2021, employing a single anti-BCMA single-chain variable fragment.
Cellular Therapies for Multiple Myeloma Part I: A CAR-T Primer for the Community Oncologist
By Aimaz Afrough, MD; Samer Al Hadidi, MD, MS; Sean Taasan, MD; Larry D Anderson Jr, MD, PhD
Ide-cel was the first anti-BCMA CAR-T product approved by the FDA in March 2021, employing a single anti-BCMA single-chain variable fragment.
Cellular Therapies for Multiple Myeloma Part I: A CAR-T Primer for the Community Oncologist
By Aimaz Afrough, MD; Samer Al Hadidi, MD, MS; Sean Taasan, MD; Larry D Anderson Jr, MD, PhD
Ide-cel was the first anti-BCMA CAR-T product approved by the FDA in March 2021, employing a single anti-BCMA single-chain variable fragment.
Daraxonrasib: The New Pancreatic Cancer Drug Patients Can Access Now Through Clinical Trial
By Krutika Gohil, MD
Results of the RASolute 302 clinical trial show Daraxonrasib nearly doubles survival with fewer side effects compared to chemotherapy for pancreatic cancer patients.
Daraxonrasib: The New Pancreatic Cancer Drug Patients Can Access Now Through Clinical Trial
By Krutika Gohil, MD
Results of the RASolute 302 clinical trial show Daraxonrasib nearly doubles survival with fewer side effects compared to chemotherapy for pancreatic cancer patients.
Daraxonrasib: The New Pancreatic Cancer Drug Patients Can Access Now Through Clinical Trial
By Krutika Gohil, MD
Results of the RASolute 302 clinical trial show Daraxonrasib nearly doubles survival with fewer side effects compared to chemotherapy for pancreatic cancer patients.
Multiple Myeloma and Plasma Cell Disorders in 2026: Earlier Bispecifics and a New Amyloidosis Target
By Laahn Foster, MD
The data presented at ASCO 2026 provide more clarity on where bispecifics fit in the treatment sequence, how long to use them, and whether they can be used as an earlier intervention.
Multiple Myeloma and Plasma Cell Disorders in 2026: Earlier Bispecifics and a New Amyloidosis Target
By Laahn Foster, MD
The data presented at ASCO 2026 provide more clarity on where bispecifics fit in the treatment sequence, how long to use them, and whether they can be used as an earlier intervention.
Multiple Myeloma and Plasma Cell Disorders in 2026: Earlier Bispecifics and a New Amyloidosis Target
By Laahn Foster, MD
The data presented at ASCO 2026 provide more clarity on where bispecifics fit in the treatment sequence, how long to use them, and whether they can be used as an earlier intervention.
Relapsed and Refractory DLBCL in 2026: More Options Than Ever, and Three Questions That Actually Matter
By Timothy Fenske, MD
Four of the five randomized R/R DLBCL trials showing overall survival benefit have come in the last four years. Dr. Timothy Fenske maps the 2026 options and the three questions that actually guide treatment selection.
Relapsed and Refractory DLBCL in 2026: More Options Than Ever, and Three Questions That Actually Matter
By Timothy Fenske, MD
Four of the five randomized R/R DLBCL trials showing overall survival benefit have come in the last four years. Dr. Timothy Fenske maps the 2026 options and the three questions that actually guide treatment selection.
Relapsed and Refractory DLBCL in 2026: More Options Than Ever, and Three Questions That Actually Matter
By Timothy Fenske, MD
Four of the five randomized R/R DLBCL trials showing overall survival benefit have come in the last four years. Dr. Timothy Fenske maps the 2026 options and the three questions that actually guide treatment selection.
Next-Generation KRAS Inhibitors in NSCLC: A Pipeline So Active It's Hard to Keep Up
By Robert Chun-Hao Hsu, MD
KRAS was considered undruggable for decades. The protein's smooth, shallow surface offered no obvious pocket for small molecule binding. Its extremely high affinity for GTP/GDP made competitive inhibition impractical.
Next-Generation KRAS Inhibitors in NSCLC: A Pipeline So Active It's Hard to Keep Up
By Robert Chun-Hao Hsu, MD
KRAS was considered undruggable for decades. The protein's smooth, shallow surface offered no obvious pocket for small molecule binding. Its extremely high affinity for GTP/GDP made competitive inhibition impractical.
Next-Generation KRAS Inhibitors in NSCLC: A Pipeline So Active It's Hard to Keep Up
By Robert Chun-Hao Hsu, MD
KRAS was considered undruggable for decades. The protein's smooth, shallow surface offered no obvious pocket for small molecule binding. Its extremely high affinity for GTP/GDP made competitive inhibition impractical.
Daraxonrasib and the RASolute 302 Trial: A Paradigm Shift in the RAS Targeting Era and Management of Pancreatic Cancer
By Ibrahim Halil Sahin, MD; Dr. Meghana Singh
For the first time, a targeted therapy has doubled overall survival in second-line metastatic pancreatic cancer. Two oncologists break down the RASolute 302 trial and what daraxonrasib means for the field.
Daraxonrasib and the RASolute 302 Trial: A Paradigm Shift in the RAS Targeting Era and Management of Pancreatic Cancer
By Ibrahim Halil Sahin, MD; Dr. Meghana Singh
For the first time, a targeted therapy has doubled overall survival in second-line metastatic pancreatic cancer. Two oncologists break down the RASolute 302 trial and what daraxonrasib means for the field.
Daraxonrasib and the RASolute 302 Trial: A Paradigm Shift in the RAS Targeting Era and Management of Pancreatic Cancer
By Ibrahim Halil Sahin, MD; Dr. Meghana Singh
For the first time, a targeted therapy has doubled overall survival in second-line metastatic pancreatic cancer. Two oncologists break down the RASolute 302 trial and what daraxonrasib means for the field.
Small Cell Lung Cancer in 2026: A Field That Has Finally Started Moving
By Deepti Behl, MD
Platinum-etoposide served as the cornerstone of therapy, producing rapid responses that were often followed by equally rapid relapses, and few effective subsequent options.
Small Cell Lung Cancer in 2026: A Field That Has Finally Started Moving
By Deepti Behl, MD
Platinum-etoposide served as the cornerstone of therapy, producing rapid responses that were often followed by equally rapid relapses, and few effective subsequent options.
Small Cell Lung Cancer in 2026: A Field That Has Finally Started Moving
By Deepti Behl, MD
Platinum-etoposide served as the cornerstone of therapy, producing rapid responses that were often followed by equally rapid relapses, and few effective subsequent options.